Secukinumab in plaque psoriasis--results of two phase 3 trials.

By R. Langley, B. Elewski, M. Lebwohl, K. Reich, C. Griffiths, K. Papp, L. Puig, H. Nakagawa, L. Spelman, B. Sigurgeirsson and 10 more. New England Journal of Medicine, 2014

1,859 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/3c80187a558674c5934e997534dbac7a70d242fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

1. Adriana Rendon
2. K. Schäkel

In Immunology

1. A. Garg
2. Nilesh Amatya
3. K. Schäkel
4. Adriana Rendon
5. S. Gaffen

In Rheumatology

1. S. Gaffen

Citations in the corpus

• Psoriasis Pathogenesis and Treatment (2019, background): “Candida infections are more frequent in patients receiving anti-IL17 biologics secukinumab and ixekizumab compared to etanercept [209].”
• IL-17 Signaling: The Yin and the Yang (2017, background): “However, only a small percentage of patients undergoing anti-IL-17 treatment (2–4%) experienced mucosal candidiasis, suggesting that blockade of this cytokines may need to be profound in order to cause this side effect [11, 28].”
• Immunopathogenesis of rheumatoid arthritis (2017, neutral): “…including IL-17A and IL-17RA inhibitors have as yet not been particularly effective in established RA trials despite remarkable responses being 190 Immunity 46, February 21, 2017 achieved in psoriasis (Langley et al., 2014) and to some extent spondyloarthropathies (McInnes et al., 2015).”